5941153bb7
Co-Authored-By: Claude Opus 4.8 <noreply@anthropic.com>
3.1 KiB
3.1 KiB
type, title, description, jurisdiction, legislature, session, identifier, citation, classification, subjects, status, primary_sponsors, version_count, action_count, vote_count, first_action, last_action, source, source_identifier, source_url, source_hash, vintage, source_snapshot, retrieved_at, confidence, tags
| type | title | description | jurisdiction | legislature | session | identifier | citation | classification | subjects | status | primary_sponsors | version_count | action_count | vote_count | first_action | last_action | source | source_identifier | source_url | source_hash | vintage | source_snapshot | retrieved_at | confidence | tags | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bill | Maryland Medical Assistance Program and Health Insurance - Specialty Drugs - Definition | Maryland Medical Assistance Program and Health Insurance - Specialty Drugs - Definition | us/states/md | Maryland General Assembly | 2020 | SB 931 | Maryland SB 931 (2020) |
|
enacted |
|
3 | 12 | 2 | 2020-02-03 | 2020-05-08 | openstates | ocd-bill/bb446cdb-6a12-4b51-9a8c-c58c488d7d13 | http://mgaleg.maryland.gov/mgawebsite/Legislation/Details/sb0931?ys=2020RS&search=True | e344df2d2a735542211452be91cb29e54caf3e30f67279f1e8ff57e013eadd0d | 2026-07-01 | https://data.openstates.org/daily/2026-07-01/public.pgdump | 2026-07-06 | reported |
|
Maryland SB 931 (2020) — Maryland Medical Assistance Program and Health Insurance - Specialty Drugs - Definition
Version chain
The bill's text revisions, in order — the diff chain from filing to enrollment.
- Chapter - Maryland Medical Assistance Program and Health Insurance - Specialty Drugs - Definition (committee substitute) — source
- First - Maryland Medical Assistance Program and Health Insurance - Specialty Drugs - Definition (committee substitute) — source
- Third - Maryland Medical Assistance Program and Health Insurance - Specialty Drugs - Definition (committee substitute) — source
Votes
- On Third Reading (Emerg) — 45–0 (pass) · upper
- On Third Reading (Emerg) — 132–0 (pass) · lower
Sponsors
- Hayes — primary (person)
Timeline
The legislative action history — every referral, reading, and vote.
- 2020-02-03 First Reading Finance
referral-committee - 2020-02-07 Hearing 3/04 at 1:00 p.m.
- 2020-03-13 Favorable with Amendments Report by Finance
committee-passage-favorable - 2020-03-13 Favorable with Amendments {
committee-passage-favorable - 2020-03-13 Second Reading Passed with Amendments
- 2020-03-14 Third Reading Passed
passage - 2020-03-15 Referred Health and Government Operations
referral-committee - 2020-03-16 Favorable Report by Health and Government Operations
committee-passage-favorable - 2020-03-17 Favorable Adopted Second Reading Passed
committee-passage-favorable - 2020-03-18 Third Reading Passed
passage - 2020-03-18 Returned Passed
- 2020-05-08 Enacted under Article II, Section 17(c) of the Maryland Constitution - Chapter 615
became-law
Source
OpenStates / OpenCivicData bulk snapshot 2026-07-01; origin ocd-bill/bb446cdb-6a12-4b51-9a8c-c58c488d7d13. Confidence: reported (aggregated from official Maryland legislature records).